Navigation Links
Investors Acquire Share in Sangui BioTech GmbH
Date:4/21/2008

WITTEN, Germany, April 21 /PRNewswire-FirstCall/ -- A group of German investors is about to acquire up to 10% of the shares of SanguiBioTech GmbH, Witten, for a purchasing price of up to EUR 750,000. The acquisition will be effectuated by way of a capital increase which will be subscribed to by the investors. It will become effective after the investment sum will have been paid in on a Sangui account and after the capital increase will have been entered in the German register of commercial companies. The majority of those investors are already engaged as shareholders of Sangui BioTech International, Inc., and by subscribing to convertible promissory notes.

Hubertus Schmelz, Managing Director of SanguiBioTech GmbH, said: "We are glad that our investors show uninterrupted confidence in Sangui's future. Their thorough understanding of the long term perspective of our products and projects is highly appreciated. This renewed investment will mainly serve to finance ongoing business as well as special initiatives to promote further development, marketing and sales activities."

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (http://www.pinksheets.com: SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49-16-07-41-27-17

Fax: +49-23-02-915-191

e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui BioTech International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont Leaders Brief Investors on Agriculture Businesses
2. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
3. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
5. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
6. XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
7. PURE Bioscience to Present at Biocom Investors Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference
9. Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for $20 Million with New and Existing Institutional Investors
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
Breaking Biology Technology:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):